Sangamo reports Q1 EPS (14c) vs (27c) last year

Reports Q1 revenue $6.44M, consensus $7.42M. “This quarter we continued to advance our promising neurology genomic medicine pipeline and are pleased to have signed our third STAC-BBB license agreement, reinforcing that Sangamo (SGMO) is a collaborator of choice for neurotropic capsids,” said Sandy Macrae, Chief Executive Officer of Sangamo Therapeutics. “We achieved significant clinical and regulatory derisking milestones in our Fabry disease program and raised additional capital through business development and other means, to provide additional runway to secure a potential Fabry partner. With our neuropathic pain program ready to enter the clinic, we look forward to dosing the first patients with our epigenetic regulation technology, which we hope will usher in a new era in chronic pain treatment.”